Formed in 2012 when former Osler Hoskin & Harcourt intellectual property stars David Aitken and Marcus Klee decamped from their former firm to set up their own eponymously named boutique, Aitken Klee was blessed with near-instant celebrity upon arrival thanks to the historic win on the part of Aitken in the landmark 2012 decision of the Supreme Court of Canada holding the patent for Viagra invalid. “David Aitken is THE toughest opponent to go against,” confirms a peer. “He’s as tough as nails and when he’s put on a case he’s at the top of his game very difficult to beat.” Based primarily in Ottawa, the firm has since expanded into Toronto, where Jonathan Stainsby provides a seasoned perspective on patent litigation and a canon of experience with Teva Canada Limited and Teva Pharmaceutical Industries regarding a wide variety of matters including pharmaceutical patent infringement actions and injunctions, proceedings under the Patented Medicines (Notice of Compliance) Regulations, commercial litigation and judicial review proceedings. “Aitken Klee are doing better than everyone thought they would be, once Teva experienced some well-publicized workforce reduction! It didn’t seem to affect the firm – they have retained a bunch of Teva files and they have diversified, pulling in other generics as well as non-pharma-related patent work.” As an example of this diversification, Aitken and Klee are representing Betser-Zilevitch in patent infringement proceedings relating to oil and gas technology. Klee and Stansby are representing Pharmascience in defence of Lilly’s claim for damages for patent infringement. The pair is also advancing a counterclaim for invalidity of the three asserted patents. The product is tadalafil (Cialis.) The pair is also representing Pharmascience in its claim for Section 8 damages related to pregabalin and zolpidem. Stainsby is representing Taro in proceedings under the PM(NOC) Regulations relating to the pharmaceutical fampridine. Michael Crinson, who joined the firm’s Toronto office in 2016 when his former firm Dimock Stratton was absorbed into DLA Piper, represents two Boston Scientific corporations and two LivaNova corporations in a multinational patent infringement suit.
